Your browser doesn't support javascript.
loading
Effect of inguinal lymph node dissection in lymph node negative patients with squamous cell carcinoma of the penis.
Tappero, Stefano; Piccinelli, Mattia; Barletta, Francesco; Panunzio, Andrea; Cano Garcia, Cristina; Incesu, Reha-Baris; Tian, Zhe; Parodi, Stefano; Dell'Oglio, Paolo; De Cobelli, Ottavio; Briganti, Alberto; Antonelli, Alessandro; Chun, Felix K H; Graefen, Markus; Saad, Fred; Shariat, Shahrokh F; Suardi, Nazareno R; Borghesi, Marco; Terrone, Carlo; Karakiewicz, Pierre I.
Afiliação
  • Tappero S; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada. stefano.m.tappero@gmail.com.
  • Piccinelli M; Department of Urology, IRCCS Policlinico San Martino, Largo R. Benzi 10, 16132, Genoa, Italy. stefano.m.tappero@gmail.com.
  • Barletta F; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genoa, Italy. stefano.m.tappero@gmail.com.
  • Panunzio A; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
  • Cano Garcia C; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
  • Incesu RB; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
  • Tian Z; Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Parodi S; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
  • Dell'Oglio P; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • De Cobelli O; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
  • Briganti A; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.
  • Antonelli A; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
  • Chun FKH; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Graefen M; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
  • Saad F; Department of Urology, IRCCS Policlinico San Martino, Largo R. Benzi 10, 16132, Genoa, Italy.
  • Shariat SF; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genoa, Italy.
  • Suardi NR; Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Borghesi M; Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Terrone C; Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Karakiewicz PI; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
World J Urol ; 41(1): 119-125, 2023 Jan.
Article em En | MEDLINE | ID: mdl-36239810
ABSTRACT

INTRODUCTION:

The survival benefit of inguinal lymph node dissection (ILND) vs no ILND in patients with squamous cell carcinoma of the penis (SCCP) and the absence of lymph node invasion is unclear. We addressed this uncertainty within the Surveillance, Epidemiology and End Results (SEER 2000-2018) database. MATERIAL AND

METHODS:

We identified lymph node negative SCCP patients who either underwent ILND (pN0) or clinical examination only (cN0). We tested for the effect of ILND vs no ILND on cancer-specific mortality (CSM) in Kaplan-Meier plots, univariable and multivariable Cox regression analyses, in a pT stage-specific fashion, before and after 13 propensity score matching (PSM). Sensitivity analyses were conducted according to historical and contemporary treatment periods as well as geographic regions.

RESULTS:

Of 2520 SCCP patients, 369 (15%) underwent ILND (pN0) vs 2151 (85%) did not (cN0). The pN0 vs cN0 distribution according to pT stages was as follows 80 (7%) vs 1092 (93%) in pT1b, and 289 (21%) vs 1059 (79%) in pT2-3. At 36 months, CSM-free survival in pT2-3 stage was 89% in ILND vs 74% in no ILND patients (multivariable hazard ratio 0.42, CI 0.30-0.60, p < 0.001). This result was confirmed in sensitivity analyses, and after 13 PSM. The same analyses could not be completed in pT1b stage due to insufficient number of observations and events.

CONCLUSIONS:

In pT2-3 stage SCCP, a significantly lower CSM was recorded in lymph node negative patients treated with ILND than in their clinical lymph node negative counterparts who did not undergo ILND.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Penianas / Carcinoma de Células Escamosas Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Penianas / Carcinoma de Células Escamosas Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article